H7N9 avian influenza is an emerging viral disease in China caused by avian influenza A (H7N9) virus. We investigated host cytokine and chemokine profiles in serum samples of H7N9 patients by multiplex-microbead immunoassays. Statistical analysis showed that IP-10, IL-6, IL-17, and IL-2 were increased in H7N9 infected patients. Furthermore, IL-6 and the chemokine IP-10 were significantly higher in severe H7N9 patients compared to nonsevere H7N9 cases. We suggest that proinflammatory cytokine responses, characterized by a combined Th1/Th17 cytokine induction, are partially responsible for the disease progression of patients with H7N9 infection.
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In March 2013, 3 urban residents of Shanghai or Anhui, China, presented with rapidly progressing lower respiratory tract infections and were found to be infected with a novel reassortant avian-origin influenza A (H7N9) virus [1] . As of June 2013, a total of 131 cases have been laboratory confirmed with influenza A (H7N9) virus in China, including 39 deaths. Most H7N9 cases are characterized by high fever and severe respiratory symptoms. Humans become infected usually after recent exposure to poultry [1] . To date, the pathogenic mechanism H7N9 infection in human has not been defined.
Human infection with highly virulent influenza viruses, together with aberrant and excessive cytokine production, are linked to morbidity and mortality. A cytokine-mediated inflammatory response, characterized by hyper-induction of proinflammatory cytokine (also known as hypercytokinemia), accompanied by a high viral load plays an important role in the disease progression and the ultimate death of patients infected with the influenza H5N1 virus [2] . However, the innate immune response to H7N9 virus infection and the role of most cytokines in disease severity remain unclear. In the present study, the concentrations of interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 12 (IL-12), interleukin 17 (IL-17), tumor necrosis factor α (TNF-α), interferon α (IFN-α), interferon γ (IFN-γ), monocyte chemoattractant protein 1 (MCP-1), interferon r-induced protein 10 (IP-10) and regulated on activation and normally T-cell expressed (RANTES) were determined in serum samples of H7N9 patients during the 2013 sporadic outbreak in Eastern China. The results of this study further our understanding of the pathogenic events leading to poor outcomes related to H7N9 infection and provide insights into novel strategies for the diagnosis and treatment of H7N9-infected patients.
METHODS
H7N9 patients (n = 16) were admitted to hospitals located in Jiangsu Province of China in 2013. All were confirmed positive for H7N9 infection by detection of viral RNA using a real-time polymerase chain reaction kit (World Health Organization [WHO] TaqMan assay) provided by the WHO Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center on 8 April 2013 (WHO, 2013b). Serum samples were collected in the acute phase (6-9 days after disease onset). For comparison, serum samples were also obtained and analyzed in parallel from H3N2 patients (n = 8), all of which were mild cases without severe influenza/pneumonia and were not hospitalized. Age-and gender-matched healthy volunteers (n = 9) who had undergone routine physical examinations in Jiangsu Province were analyzed as healthy controls. The exclusion criteria for healthy control individuals were as follows: acute or chronic infectious disease, any clinically significant disorder, any medication with known influence on immunological factors. According to the medical research regulation of the Ministry of Health of China, all individuals involved in the study provided informed consent and were ensured of confidentiality and anonymity.
Serum cytokines (IL-2, IL-4, IL-6, IL-10, IL-12, IL-17, IFN-γ, IP-10, TNF-α, and RANTES) were measured in a multiplexbiometric immunoassay containing fluorescent microspheres conjugated with target-specific monoclonal antibodies according to the manufacturer's instructions (Bio-plex Pro Human 10-plex cytokine panel, Bio-Rad, CA). Serum IFN-α and MCP-1 were analyzed by ELISA (BioLegend, San Diego, CA) according to the manufacturer's protocol.
Unpaired t tests were used to analyze differences between two groups. Comparisons of the means of more than two groups were performed using one-way analysis of variance (ANOVA). P < .05 was considered to indicate a significant difference. Results were analyzed using SPSS for Windows version 17.0 (SPSS, Chicago, IL).
RESULTS
Five (31.3%) fatalities were recorded among the 16 H7N9-infected patients enrolled in this study. The mean age of the patients was 48.5 years, and 9 (56.3%) were male ( Table 1) . Five (31.3%) had contact history with poultry. The median interval from the onset of illness to first medical visit was 1.56 days. Fever and lower respiratory tract symptoms (including cough, sputum, and dyspnea) were the most frequent symptoms. Eleven (68.8%) patients had comorbidities including hypertension, diabetes, coronary heart disease, cancer, cerebrovascular disease and hepatitis B infection. Eleven (68.8%) were treated with antiviral drugs, 8 (50%) with corticosteroids therapy, and 5 (31.3%) with immunomodulatory agents before sampling. The demographic and clinical characteristics of H3N2-infected patients and healthy controls are provided in Table 1 .
According to Diagnostic and Treatment Protocol for Human infections with Avian Influenza A (H7N9) (2nd edition, 2013) issued by the National Health and Family Planning Commission, the major clinical symptoms in severe cases were acute respiratory distress syndrome (ARDS), pneumonia and respiratory failure in addition to fever and productive cough. Thirteen (81.3%) patients met the criteria for severe disease with ARDS, respiratory failure, and a requirement for mechanical ventilation ( Table 1 ). The median interval between illness onset and development of respiratory failure in severe patients was 7.8 days. Bilateral ground-glass opacities and consolidation were the most common radiologic findings in severe patients. Only slight radiographic changes in the lung, including thickened lung markings or small amounts of local inflammatory infiltration shadows were found in mild cases. Age, highest temperature, and white blood cell counts were similar among the severe and nonsevere cases (P > .05). There was no statistically significant difference in the leukocyte types between severe and nonsevere cases.
As shown in Figure 1A , there were no statistically significant differences in the serum levels of IL-10, IL-12, IFN-α, IFN-γ, MCP-1, and RANTES between H7N9-, H3N2-infected patients, and healthy controls. The IL-4 and TNF-α levels were lower in H3N2 patients compared with healthy controls. However, levels of the Th1 cytokines, IL-6 (P = .007 H7N9 vs control; P = .016 H7N9 vs H3N2) and IP-10 (P = .001 H7N9 vs control; P = .002 H7N9 vs H3N2), were significantly higher in H7N9 cases compared to H3N2 patients and healthy controls. Serum levels of IL-2 (P = .009) and IL-17 (P = .018) were significantly higher in H7N9 cases compared to healthy controls ( Figure 1B) . These results indicated that H7N9 infection induced Th1-type (IL-2, IL-6, IP-10) and Th17-type (IL-17) cytokine secretion, suggesting that an intense inflammatory response to virus infection, perhaps specifically involving recruitment of inflammatory cells to infected tissues, contributes to disease pathogenesis.
As shown in Figure 1C , there were no statistically significant differences in the serum levels of IL-4, IL-10,IL-12, IL-17, IFN-α, MCP-1, TNF-α, and RANTES between severe and nonsevere H7N9 patients during the acute phase or the healthy controls. Although serum IL-2 levels were increased in severe H7N9 cases compared to healthy controls, there was no statistically significant difference between H7N9 severe and patients. However, compared with nonsevere cases, IP-10 (P = .005) and IL-6 (P = .024) were significantly higher in H7N9 severe cases ( Figure 1D ). IFN-γ levels in nonsevere cases were significantly higher than those in healthy individuals (P = .049) and severe cases (P = .039). These data indicate that increased levels of IP-10 and IL-6 in severe H7N9 patients may reflect the severity of the disease. The cytokine and chemokine levels in sequential plasma samples of 5 H7N9 patients are shown in Figure 2 (results for each patients are shown separately due to the small sample size and the variation in sampling times between patients).
DISCUSSION
In March 2013, a life-threatening disease characterized by fever, ARDS and respiratory failure was first reported in Eastern China. A novel reassortant H7N9 virus was identified as the causative agent of this disease. In this study, we found that proinflammatory cytokine responses, characterized by a combined Th1/Th17 cytokine induction, are partially responsible for the disease progression of patients with H7N9 infection.
Virus-induced cytokine dysregulation in the acute phase of disease has been widely hypothesized to be the main cause of morbidity and mortality in several viral infections [3] [4] [5] [6] . To identify potential immune mediators contributing to disease severity, we investigated cytokine and chemokine levels and found dysregulation of multiple proinflammatory cytokines in H7N9 patients during the acute phase of infection. In this study we demonstrated that H7N9 viruses were potent inducers of proinflammatory cytokines (eg, IL-2, IL-6, and IL-17) and chemokines (eg, IP-10) which may function in concert to clear pathogens and regulate cellular immune responses but may also mediate destructive tissue inflammation. Furthermore, compared to nonsevere cases, severe H7N9 patients had unusually high serum levels of IP-10 and IL-6, which may reflect the severity of the disease. The cause of the significantly higher levels of IFN-γ in nonsevere H7N9 cases may indicate a suppression of IFN-γ responses and the failure of antiviral immunity in patients with severe illness. Chen et al [7] reported that the serum concentrations of IL-10 were persistently increased in a single fatal case of severe H7N9 infection compared to a single nonfatal case. However, there were no statistically significant differences observed of IL-10 levels in our research when we increased the patient numbers. The increased IL-10 levels in the fatal H7N9 patient that reported in Chen's study may due to the individual difference. Here, we found no significant differences in the levels of a broad panel of cytokines/chemokines in fatal and nonfatal H7N9 cases (data not shown). . Note: The vertical axes differ for each of the mediators to accommodate the extreme variation in the normal distributed range of cytokine concentrations. Data represent means ± SD (Control, n = 9; H3N2, n = 8; H7N9, n = 16; severe H7N9, n = 13; nonsevere H7N9, n = 3). *P < .05, **P < .01. Abbreviations: IL, interleukin; IFN-γ, interferon γ; IP, induced protein; RANTES, regulated on activation and normally T-cell expressed; SD, standard deviation; TNF-α, tumor necrosis factor α.
Variable Th1-type and Th17-type responses have previously been described in severe H1N1 pdm09 infections, which have been shown to induce a typical innate response in both mild and severe patients. Severe disease with respiratory involvement is characterized by secretion of Th17 and Th1 cytokines [8] , or production of a number of cytokines including IL-6, IL-10 [9] , IL-15, IL-8, and TNF-α [10] . Our data are consistent with these findings to some extent, in that H7N9 infection induced secretion of Th1-type (IL-2, IL-6, IP-10) and Th17-type (IL-17) cytokines. These types of cytokine profile are indicative of an intense inflammatory response to virus infection but are also commonly linked to the pathogenesis of autoimmune/inflammatory diseases. Our present study showed that IP-10 and/or IL-6 are elevated in severe H7N9 cases, which is consistent with findings in H5N1 [2, 11] , SARS [12] , and severe H1N1 pdm09 patients [9] , indicating that IP-10 and/or IL-6 play a critical role in virusmediated severe respiratory diseases.
It should be noted that interpretation of our results is limited by the small sample size, difficulty in obtaining samples from intensive care unit patients and clinical variability. With the restriction of sampling, our current study cannot test the cytokine/chemokine levels in respiratory tract secretions. Furthermore, because of the different sample sources for virus detection (7 were sputum specimens, 9 were throat swabs) that may influence the virus Ct values and the use of antivirals, corticosteroids, or other immunomodulatory agents that may influence the cytokine/chemokine levels, there were no notable correlations observed between viral titers and cytokine responses (data not shown). Nevertheless, our results demonstrate an association between cytokine and chemokine production and the clinical severity of H7N9 infection, and further studies are warranted to establish the exact involvement of viral and/or host factors in priming these immunological responses.
In this report we observed an activated innate immune response after H7N9 infection manifested as combined Th1/ Th17 cytokine induction. As disease progresses, an overwhelming induction of IL-6 and IP-10 was observed in severe H7N9 patients. The hyperactive cytokine-mediated inflammatory response may result in destructive tissue inflammation and contributing to the increased severity of H7N9 infection. We believe that this proinflammatory cytokine responses pattern, which is critical to viral pathogenesis in the H7N9 infection, could serve as biomarkers to aid physicians evaluating the disease severity of H7N9 patients. Furthermore, immunomodulatory treatment through preventing the intense cytokine responses accompanied by antiviral treatment could be an effective therapeutic strategy for H7N9 infection.
Notes

